 PALO ALTO, Calif., Jan. 25, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO the Company, we or BridgeBio announced today the pricing of 650 million aggregate principal amount of 2.25 convertible senior notes due 2029 the notes in a private offering the offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended the Securities Act. The offering was upsized from the previously announced offering of 400 million aggregate principal amount of notes. In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional 97.5 million aggregate principal amount of notes. The sale of the notes is expected to close on January 28, 2021, subject to customary closing conditions. 